Payment overview · 2025
General Payments
$14,530.08
132 reported records · 27 companies
Healthcare provider profile · identity verified
Mahir Darrar Elder, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · DETROIT, MI · NPI 1962427260
Verified facts
What the public records show
CMS Open Payments records show Mahir Darrar Elder, MD received $14,530.08 in general payments during 2025 across 132 reported records.
AngioDynamics, Inc. accounted for 43.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Verquvo, Wegovy.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 590 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 530 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 440 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 536 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 590 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $6,333.33 | 43.6% | 1 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $4,942.91 | 34.0% | 2 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $382.42 | 2.6% | 15 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $290.89 | 2.0% | 12 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $277.53 | 1.9% | 3 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $273.87 | 1.9% | 14 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $195.42 | 1.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $190.80 | 1.3% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $185.64 | 1.3% | 8 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $163.22 | 1.1% | 6 | 2025 |
| Inquis Medical, Inc. | Unresolved — no canonical attribution shown | $151.32 | 1.0% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $145.41 | 1.0% | 6 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $136.50 | 0.9% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $116.53 | 0.8% | 5 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $107.72 | 0.7% | 7 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $106.96 | 0.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $90.89 | 0.6% | 5 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $74.06 | 0.5% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $69.91 | 0.5% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$66.88 | 0.5% | 3 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $50.92 | 0.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $43.02 | 0.3% | 2 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $36.18 | 0.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.16 | 0.2% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $28.09 | 0.2% | 1 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $25.42 | 0.2% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $14.08 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $6,333.33 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,800.00 | 1 |
| Food and Beverage | $3,396.75 | 130 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auryon Laser System 100-120 Vac Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $6,333.33 | 1 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $4,942.91 | 2 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $382.42 | 15 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $201.45 | 7 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $197.53 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $190.80 | 9 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $163.22 | 6 | 2025 |
Source payment records
|
|||||
| Aventus Normalized: aventus |
Device | Inquis Medical, Inc. | $151.32 | 1 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $149.66 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $149.02 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $145.41 | 6 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $145.41 | 6 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $136.50 | 11 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $124.46 | 7 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $107.72 | 7 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $107.46 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $106.96 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $90.89 | 5 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $81.51 | 3 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $74.06 | 3 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $66.88 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $62.02 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $62.02 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.35 | 4 | 2025 |
Source payment records
|
|||||
| AFX2 Bifurcated Endograft System Normalized: afx2 bifurcated endograft system |
Device | Endologix LLC | $53.62 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $50.92 | 2 | 2025 |
Source payment records
|
|||||
| PRODIGY CATHETER Normalized: prodigy catheter |
Device | Imperative Care, Inc | $45.76 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $43.02 | 2 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $40.58 | 2 | 2025 |
Source payment records
|
|||||
| Artis zee multi-purpose Normalized: artis zee multi purpose |
Device | Siemens Medical Solutions USA, Inc. | $36.18 | 1 | 2025 |
Source payment records
|
|||||
| SOMATOM go.Top Normalized: somatom go top |
Device | Siemens Medical Solutions USA, Inc. | $36.18 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.16 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $29.33 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $28.09 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $27.94 | 1 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $14.95 | 2 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $14.95 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $11.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 590 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 151 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 281 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 530 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
172 | 57 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
151 | 42 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
281 | 90 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
590 | 169 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
281 | 90 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
530 | 140 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
167 | 49 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
440 | 122 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
536 | 120 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
590 | 169 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 815 | 263 |
| Atorvastatin Calcium | Atorvastatin Calcium | 691 | 237 |
| Clopidogrel | Clopidogrel Bisulfate | 664 | 187 |
| Eliquis | Apixaban | 590 | 169 |
| Carvedilol | Carvedilol | 563 | 180 |
| Ozempic | Semaglutide | 536 | 120 |
| Mounjaro | Tirzepatide | 530 | 140 |
| Metoprolol Tartrate | Metoprolol Tartrate | 466 | 192 |
| Entresto | Sacubitril/Valsartan | 440 | 122 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 329 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 306 | 107 |
| Losartan Potassium | Losartan Potassium | 301 | 104 |
| Xarelto | Rivaroxaban | 288 | 95 |
| Lisinopril | Lisinopril | 286 | 103 |
| Jardiance | Empagliflozin | 281 | 90 |
| Ranolazine Er | Ranolazine | 268 | 64 |
| Spironolactone | Spironolactone | 266 | 103 |
| Furosemide | Furosemide | 260 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 68 |
| Nitroglycerin | Nitroglycerin | 182 | 60 |
| Brilinta | Ticagrelor | 172 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 169 | 62 |
| Trulicity | Dulaglutide | 167 | 49 |
| Simvastatin | Simvastatin | 158 | 53 |
| Potassium Chloride | Potassium Chloride | 156 | 54 |
| Farxiga | Dapagliflozin Propanediol | 151 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 56 |
| Metformin Hcl | Metformin Hcl | 131 | 50 |
| Hydralazine Hcl | Hydralazine Hcl | 126 | 47 |
| Repatha Sureclick | Evolocumab | 118 | 26 |
| Chlorthalidone | Chlorthalidone | 111 | 41 |
| Nifedipine Er | Nifedipine | 105 | 41 |
| Cilostazol | Cilostazol | 103 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 96 | 31 |
| Bumetanide | Bumetanide | 90 | 35 |
| Omeprazole | Omeprazole | 72 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 71 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 20 |
| Clonidine Hcl | Clonidine Hcl | 51 | 16 |
| Ezetimibe | Ezetimibe | 46 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 17 |
| Meclizine Hcl | Meclizine Hcl | 41 | 21 |
| Torsemide | Torsemide | 41 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 38 | 15 |
| Prednisone | Prednisone | 38 | 26 |
| Diltiazem Hcl | Diltiazem Hcl | 34 | 11 |
| Klor-Con M20 | Potassium Chloride | 34 | 13 |
| Praluent Pen | Alirocumab | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | 12 |
| Atenolol | Atenolol | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 21 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Multaq | Dronedarone Hcl | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Gabapentin | Gabapentin | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Verquvo | Vericiguat | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14,530.08 · 132 records | AngioDynamics, Inc. | AFX2 Bifurcated Endograft System, AIRSUPRA, AMPLATZER AMULET, AMVUTTRA, Alto Abdominal Stent Graft System, Artis zee multi-purpose, Assure WCD, Attruby, Auryon Laser System 100-120 Vac, Aventus, BREZTRI, CAMZYOS, CAPVAXIVE, CARDIVA VASCADE 6/7F VCS, ELIQUIS, EMBLEM MRI S-ICD, ENDOCROSS Device, FARXIGA, FFRct, Flexitouch Plus, GALLANT, Indigo System, JARDIANCE, LEQVIO, LifeVest, MOUNJARO, Nimbl, PRODIGY CATHETER, RHYTHM EXPRESS, SOMATOM go.Top, SYMPHONY CATHETER, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, Torus Stent Graft System, Tyvaso, VENASEAL, VERQUVO, VYNDAQEL, WAINUA, WATCHMAN FLX, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error